"Functional Equivalence" Survives In '05: Aranesp, Procrit Payment Unchanged In OPPS
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s darbepoetin will continue to be reimbursed on par with J&J’s epoetin, using a coversion formula of 330:1, in the hospital outpatient setting. CMS no longer uses the "functional equivalence" terminology, but the agency still wants "equitable" payment for the two EPO brands.
You may also be interested in...
Hospital Outpatient Drugs To Be Reimbursed ASP+8% Under Medicare In 2006
CMS issues hospital Outpatient Prospective Payment System proposed rule for 2006. Reimbursement for specified covered outpatient drugs would be switched from the current 83% of average wholesale price to average sales price plus 8% in 2006; the rate includes ASP+6% for drug acquisition costs, plus 2% of ASP for "overhead" costs.
Hospital Outpatient Drugs To Be Reimbursed ASP+8% Under Medicare In 2006
CMS issues hospital Outpatient Prospective Payment System proposed rule for 2006. Reimbursement for specified covered outpatient drugs would be switched from the current 83% of average wholesale price to average sales price plus 8% in 2006; the rate includes ASP+6% for drug acquisition costs, plus 2% of ASP for "overhead" costs.
Anti-Emetics Will Get Separate Payment Codes Under Medicare Outpatient Rule
Aventis' Anzemet, Roche's Kytril and GlaxoSmithKline's Zofran would be paid separately rather than packaged with other therapeutic services under proposed rule. Reimbursement for MGI's Aloxi will equal new ASP-based payments for physicians in the office setting.